Facebook
X
LinkedIn
ForwardNew and Emerging Treatments for Pulmonary Fibrosis
Target Audience
The series is designed for pathologists, pulmonologists, radiologists, rheumatologists, and other health providers who care for people with ILD.
Learning Objectives
- Summarize the key findings from data supporting the use of pirfenidone, nintedanib, and nerandomilast for IPF and PPF
- Compare the major risks and side effects of the different antifibrotic options
- Explain how nerandomilast can be incorporated into treatment algorithms for IPF and PPF
Time | Didactic Presentation / Case Discussion | Presenter |
7:00am-7:05am | Announcements and Introductions | Aliaa Barakat, PhD Robert Hallowell, MD |
7:05am-7:25am | New and Emerging Treatments for Pulmonary Fibrosis | Barry Shea, MD |
7:25am-8:00am | Case Presentation and Discussion | Robert Hallowell, MD |
8:00am | Closing Remarks | Aliaa Barakat, PhD |
Medical Director:
Robert Hallowell, MD
Principal Investigator:
Aliaa Barakat, PhD
Didactic Speaker:
Barry Shea, MD
Discussion Facilitator and Case Presenter:
Robert Hallowell, MD
Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.
Name | Disclosure of Relevant Financial Relationships | |
Aliaa Barakat, PhD | Dr. Barakat has no relevant financial relationships to disclose. | |
Katharine Black, MD | Dr. Black has no relevant financial relationships to disclose. | |
Fiona Gibbons, MD | Dr. Gibbons has no relevant financial relationships to disclose. | |
Leo Ginns, MD | Dr. Ginns is a clinical trial site principal investigator for United Therapeutics. | |
Robert Hallowell, MD | Dr. Hallowell has served on advisory boards and as an investigator for Boehringer Ingelheim. He has served as a consultant and an investigator for Vicore. He has also been a consultant for Merck and receives authorship fees from Up-to-Date and Dynamed. | |
Sydney Montesi, MD | Dr. Montesi is a consultant and on the clinical adjudication committee for AbbVie. She is also a consultant for Amgen, Accendatech, and Mediar Therapeutics. She receives research funding from Boehringer Ingelheim, and Pliant Therapeutics via her institution. She also receives authorship fees from Wolters Kluwer. | |
Grace Peloquin, MD | Dr. Peloquin has no relevant financial relationships to disclose. | |
Barry Shea, MD | Dr. Shea is a clinical trial site principal investigator for Boehringer Ingelheim, Bristol Myers Squibb, and Mediar Therapeutics. He has served as a consultant for Continuum Therapeutics, Radius Health, and United Therapeutics. | |
Accreditor Disclosure
Michael Burk, Senior Operations Manager for Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education has no relevant financial relationships to disclose.
Off-Label Discussion
The faculty does plan on discussing unlabeled/investigational uses of a commercial product.
All relevant financial relationships listed for these individuals have been mitigated.
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and the ILD Collaborative. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Pathology’s (ABPath) Maintenance of Certification (MOC) program. Credit type: Lifelong Learning (CME)
By participating and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABIM and ABPath.
Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Accreditation
Nursing Contact Hours: 1.0, all of which is eligible for pharmacology credit.
This activity is supported by the ILD Collaborative and by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Available Credit
- 1.00 ABIM Medical Knowledge
- 1.00 ABPATH Lifelong Learning
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC
- 1.00 ANCC Pharmacology
- 1.00 Participation